Mahboobeh Nazari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mahboobeh Nazari has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Rahman Emamzadeh
Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran
5 shared publicationsMaryam Nazari
Mahboubbioesearch co, Tehran, Iran
2 shared publicationsArash Minai-Tehrani
Nanobiotechnology Research Center
1 shared publicationElnaz Yazdani
Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
1 shared publicationFereshteh Abdolmaleki
Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
1 shared publicationMaryam Jahanpanah
Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
1 shared publication
Latest Publications
- 14 May 2025
- Published by Elsevier in Journal of Chromatography B
- Vol. 1261, 124655
Immobilization of albumin binding domain (ABD) on Sepharose 4B and magnetic particle for efficient single-step purification of human serum albumin
- 14 May 2025
- Published by Elsevier in Journal of Chromatography B
- Vol. 1261, 124655
Immobilization of albumin binding domain (ABD) on Sepharose 4B and magnetic particle for efficient single-step purification of human serum albumin
- 3 February 2025
- Published by Elsevier in Enzyme and Microbial Technology
- Vol. 185, 110603
Development of an enzymatic aptasensor for monitoring recombinant His-tagged proteins in microbial biotechnology
- 3 February 2025
- Published by Elsevier in Enzyme and Microbial Technology
- Vol. 185, 110603
Development of an enzymatic aptasensor for monitoring recombinant His-tagged proteins in microbial biotechnology
- 28 August 2022
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 219, 1122-1134
A recombinant affitoxin derived from a HER3 affibody and diphteria-toxin has potent and selective antitumor activity
- 28 August 2022
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 219, 1122-1134
A recombinant affitoxin derived from a HER3 affibody and diphteria-toxin has potent and selective antitumor activity
- Open Access
- 1 January 2022
- Published by Knowledge E DMCC in Avicenna Journal of Medical Biotechnology
- Vol. 14 (1) , 30-36
New Generation Vaccines for COVID-19 Based on Peptide, Viral Vector, Artificial Antigen Presenting Cell, DNA or mRNA
At present, effective vaccines have been developed as the most successful approaches for preventing widespread infectious disease. The global efforts are focusing with the aim of eliminating and overcoming the Coronavirus Disease 2019 (COVID-19) and are developing vaccines from the date it was announced as a pandemic disease. In this study, PubMed, Embase, Cochrane Library, Clinicaltrial.gov, WHO reports, Science Direct, Scopus, Google Scholar, and Springer databases were searched for finding the relevant studies about the COVID-19 vaccines. This article provides an overview of multiple vaccines that have been manufactured from December 2020 up to April 2021 and also offers a perspective on their efficacy, safety, advantages, and limitations. Currently, there are several categories of COVID-19 vaccines based on Protein Subunit (PS), Inactivated Virus (IV), Virus Like Particle (VLP), Live Attenuated Virus (LAV), Viral Vector (replicating) (VVr) and Viral Vector (non-replicating) (VVnr) in progress or finalized as indicated by the WHO reporting of April 1, 2020.
- 1 January 2022
- Published by Knowledge E DMCC in Avicenna Journal of Medical Biotechnology
- Vol. 14 (1) , 30-36
Open AccessNew Generation Vaccines for COVID-19 Based on Peptide, Viral Vector, Artificial Antigen Presenting Cell, DNA or mRNA
At present, effective vaccines have been developed as the most successful approaches for preventing widespread infectious disease. The global efforts are focusing with the aim of eliminating and overcoming the Coronavirus Disease 2019 (COVID-19) and are developing vaccines from the date it was announced as a pandemic disease. In this study, PubMed, Embase, Cochrane Library, Clinicaltrial.gov, WHO reports, Science Direct, Scopus, Google Scholar, and Springer databases were searched for finding the relevant studies about the COVID-19 vaccines. This article provides an overview of multiple vaccines that have been manufactured from December 2020 up to April 2021 and also offers a perspective on their efficacy, safety, advantages, and limitations. Currently, there are several categories of COVID-19 vaccines based on Protein Subunit (PS), Inactivated Virus (IV), Virus Like Particle (VLP), Live Attenuated Virus (LAV), Viral Vector (replicating) (VVr) and Viral Vector (non-replicating) (VVnr) in progress or finalized as indicated by the WHO reporting of April 1, 2020.
- 10 September 2014
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 4 (85) , 45128-45135
Comparison of different probes based on labeled annexin V for detection of apoptosis
Schematic representation of the different probes based on annexin V for the detection of apoptosis.
- 10 September 2014
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 4 (85) , 45128-45135
Comparison of different probes based on labeled annexin V for detection of apoptosis
Schematic representation of the different probes based on annexin V for the detection of apoptosis.
- 12 May 2014
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 6 (12) , 4199-4204
Adherent state apoptosis assay (ASA): a fast and reliable method to detect apoptosis in adherent cells
Apoptosis is a tightly controlled biochemical process for cell death. Although the induction of apoptosis is an important mechanism for the screening of many valuable products such as drugs, due to the false signals that usually occur during the isolation of cells from the surface of the culture plate, techniques have limitations in measuring apoptosis in adherent cells. In this study, we investigated the use of RLuc/Annexin V, a probe obtained by the fusion of Renilla luciferase (RLuc) with Annexin V and bound to phosphatidylserine (PS) on the surface of suspended apoptotic cells, as a potentially luminescent probe to assay apoptosis in adherent cells such as Chinese Hamster Ovary (CHO) cells. The probe was overexpressed in Escherichia coli BL21 (DE3) and purified by immobilized metal ion chromatography. The probe assayed for detection of apoptosis in CHO cells. The results show that RLuc/Annexin V binds to the CHO cells with no additional treatment for cell suspension, and the signal of RLuc can be detected by a luminometer. The new assay based on RLuc/Annexin V was named as adherent state apoptosis assay (ASA). This may be a new method for studying apoptosis in adherent cells in a rapid, reliable, and non-invasive way.
- 12 May 2014
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 6 (12) , 4199-4204
Adherent state apoptosis assay (ASA): a fast and reliable method to detect apoptosis in adherent cells
Apoptosis is a tightly controlled biochemical process for cell death. Although the induction of apoptosis is an important mechanism for the screening of many valuable products such as drugs, due to the false signals that usually occur during the isolation of cells from the surface of the culture plate, techniques have limitations in measuring apoptosis in adherent cells. In this study, we investigated the use of RLuc/Annexin V, a probe obtained by the fusion of Renilla luciferase (RLuc) with Annexin V and bound to phosphatidylserine (PS) on the surface of suspended apoptotic cells, as a potentially luminescent probe to assay apoptosis in adherent cells such as Chinese Hamster Ovary (CHO) cells. The probe was overexpressed in Escherichia coli BL21 (DE3) and purified by immobilized metal ion chromatography. The probe assayed for detection of apoptosis in CHO cells. The results show that RLuc/Annexin V binds to the CHO cells with no additional treatment for cell suspension, and the signal of RLuc can be detected by a luminometer. The new assay based on RLuc/Annexin V was named as adherent state apoptosis assay (ASA). This may be a new method for studying apoptosis in adherent cells in a rapid, reliable, and non-invasive way.